Intrinsic immune properties of carrier MSC impact on the clinical outcome of children with solid tumors receiving oncolytic virotherapy [0.03%]
载体间充质干细胞的内在免疫特性影响儿童实体瘤患者病毒溶瘤治疗的临床疗效
Alvaro Morales-Molina,Lidia Franco-Luzón,Patricia Garcia-Rodriguez et al.
Alvaro Morales-Molina et al.
Our previous clinical data showed that autologous mesenchymal stromal cells (MSCs) can be used as carriers for the systemic delivery of oncolytic adenoviruses in children with advanced cancers, a therapy known as Celyvir. Despite achieving ...
Dual targeting of GPX4 and TXNRD1 triggers eradication of AML cells through induction of apoptosis and ferroptosis [0.03%]
GPX4和TXNRD1双靶点通过诱导凋亡和铁死亡触发AML细胞根除
Cécile Favreau,Maxence Bourgoin,Coline Savy et al.
Cécile Favreau et al.
Myelodysplastic syndromes (MDS) are hematological disorders associated with bone marrow failure and abnormal hematopoietic cell growth, often progressing to acute myeloid leukemia (AML). Current treatments for AML and high-risk MDS are limi...
The novel retinoid WYC-209 sensitizes multiple myeloma to carfilzomib via epigenetically upregulating ZMYND8 [0.03%]
新颖的维甲酸WYC-209通过表观遗传学上调ZMYND8来使卡非佐米敏化多发性骨髓瘤
Jiaxuan Xu,Jie Yan,Haoyu Zhang et al.
Jiaxuan Xu et al.
Carfilzomib (CFZ) is a cornerstone therapy for patients with relapsed multiple myeloma (MM); however, poor prolonged treatment response remains a major clinical limitation. ZMYND8 overexpression increases the sensitivity of MM cells to CFZ....
Functional xenogeneic hematopoietic cells maintaining donor-dominant identity and immune tolerance enable therapy [0.03%]
具有供体主导身份和免疫耐受功能的异基因造血细胞能够维持移植治疗
Shumin Xiong,Ren Zhou,Chuijin Wei et al.
Shumin Xiong et al.
Background: The clinical supply of hematopoietic cells is severely constrained by the limitations of donor donation and inefficient in vitro generation. While generating these cells within interspecies chimeras presents a...
RNA-based co-transfer of human CD8αβ with WT1-specific TCRαβ redirects tumor recognition by CD4 and γδ T-cells towards MHC class I-restricted WT1 epitopes and boosts CD8 T-cell responses with or without CD3 mRNA [0.03%]
基于RNA共传递人CD8αβ与WT1特异性TCRαβ将CD4和γδT细胞重定向至MHC-I限制性WT1表位并增强有或无CD3mRNA的CD8T细胞反应
Diana Campillo-Davo,Donovan Flumens,Zwi N Berneman et al.
Diana Campillo-Davo et al.
We evaluated the redirection of CD4, γδ and CD8 T-cells towards the Wilms' tumor protein (WT1) tumor-associated antigen, using a major histocompatibility complex (MHC) class I-restricted WT1-specific T-cell receptor (TCR) introduced via R...
Novel non-viral in vivo CAR-T therapies: latest updates from the 2025 ASH annual meeting [0.03%]
新型非病毒体内CAR-T疗法：2025年ASH年会最新报告
Bin Xue,Yifan Liu,Aibin Liang et al.
Bin Xue et al.
The field of chimeric antigen receptor (CAR)-T cell therapy is undergoing a paradigm shift from complex ex vivo manufacturing to direct in vivo generation of CAR-T cells. This innovative approach leverages non-viral delivery platforms to re...
Prospects and advances of PROTAC in the treatment of hematologic malignancies [0.03%]
蛋白降解嵌合体(PROTAC)在血液系统恶性肿瘤治疗中的前景和进展
Xinyang Wang,Ming Zhang,Heng Mei
Xinyang Wang
Over the past years, target protein degradation (TPD) has emerged as a hot topic in treating hematologic malignancies out of its strong ability to eliminate pathological proteins precisely. And as a flagship, Proteolysis-Targeting Chimeras ...
JingHui Liang,JunXi Wu,Yuan Zhang et al.
JingHui Liang et al.
KRAS is the most frequently altered oncogenic driver in human cancer. Its mutations drive the initiation and progression of many solid tumors. Clinical validation of covalent KRASG12C inhibitors marked a step change and renewed focus on all...
Efficacy and safety of ruxolitinib for graft-versus-host disease prophylaxis in patients with aplastic anemia undergoing PBSC-only allogeneic stem cell transplantation: a prospective phase II study [0.03%]
拉鲁利替尼预防性治疗骨髓增生异常综合征/阵发性夜間血红蛋白尿 Hybrid型向急性髓系白血病转型的临床研究
Xiaoyu Zhang,Lulu Pan,Yanhong Zhao et al.
Xiaoyu Zhang et al.
Background: While peripheral blood hematopoietic stem cell transplantation (PB-HSCT) supports rapid engraftment and reduces graft failure risk in aplastic anemia (AA) patients, it compromised higher risk of acute graft-ve...
In vivo CAR-T engineering: insights from the 2025 ASH annual meeting [0.03%]
2025年ASH年会解读：体内CAR-T工程化最新进展
Gelayol Asadi,Misagh Rajabinejad
Gelayol Asadi
In vivo chimeric antigen receptor (CAR)-T engineering is a prominent field of research in cancer immunology, in which vectors are used to reprogram endogenous T-cells into CAR-T cells. Viral and nonviral platforms presented at the 67th Annu...